Search in:

Advanced search

Expert Review of Cardiovascular Therapy Volume 16, 2018 - Issue 8

Submit an article Journal homepage

728

Views

CrossRef citations to date

Altmetric

Review

Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction

Gilman D. PlittDepartment of Clinical & Translational Science, Creighton University School of Medicine, Omaha, NE, USAView further author information

Jordan T. SpringDepartment of Clinical & Translational Science, Creighton University School of Medicine, Omaha, NE, USAView further author information

Michael J. MoultonDepartment of Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, NE, USAView further author information

Devendra K. AgrawalDepartment of Clinical & Translational Science, Creighton University School of Medicine, Omaha, NE, USACorrespondence[email protected]

http://orcid.org/0000-0001-5445-0013 View further author information

Pages 579-589 | Received 13 Mar 2018, Accepted 03 Jul 2018, Published online: 16 Jul 2018

Cite this article
https://doi.org/10.1080/14779072.2018.1497485
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Alagiakrishnan K, Banach M, Jones LG, et al. Update on diatolic heart failure or heart failure with preserved ejection fraction in the older adults. Ann Med. 2013;45:37–50.
PubMed Web of Science ®Google Scholar
De Keulenaer GW, Brutsaert DL. Are systolic and diastolic heart failure overlapping phenotypes within the heart failure spectrum. Circ. 2011;123:1996–2004.
PubMed Web of Science ®Google Scholar
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol. 2013;62:e147–239.
PubMed Web of Science ®Google Scholar
Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology. Eur J Heart Fail. 2016;18:891–975.
PubMed Web of Science ®Google Scholar
Lam CSP, Roger VL, Rodeheffer RJ, et al. Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted county, Minnesota. Circ. 2007;115:1982–1990.
PubMed Web of Science ®Google Scholar
Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circ. 2000;101:2118–2121.
PubMed Web of Science ®Google Scholar
Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics – 2017 update: a report from the American heart association. Circ. 2017;135:e146–e603.
PubMed Web of Science ®Google Scholar
Parikh JD, Hollingsworth KG, Wallace D, et al. Normal age-related changes in left ventricular function: role of afterload and subendocardial dysfunction. Int J Cardiol. 2016;223:306–312.
PubMed Web of Science ®Google Scholar
Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the united states: a policy statement from the american heart association. Circ Heart Fail. 2013;6:606–619.
PubMed Web of Science ®Google Scholar
Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis. 2005;47:320–332.
PubMed Web of Science ®Google Scholar
Lam CSP, Donal E, Kraigher-Krainer E, et al. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13:18–28.
PubMed Web of Science ®Google Scholar
Chan MMY, Lam CSP. How do patients with heart failure with preserved ejection fraction die? Eur J Heart Fail. 2013;15:604–613.
PubMed Web of Science ®Google Scholar
Upadhya B, Kitzman DW. Heart failure with preserved ejection fraction in older adults. Heart Fail Clin. 2017;13:485–502.
PubMed Web of Science ®Google Scholar
Siddiqi OK, Ruberg FL. Cardiac amyloidosis: an update on pathophysiology, diagnosis, and treatment. Trends Cardiovasc Med. 2018;28:10–21.
PubMed Web of Science ®Google Scholar
Nihoyannopoulos P, Dawson D. Restrictive cardiomyopathies. Eur J Echocardiogr. 2009;10:iii23–iii33.
PubMed Web of Science ®Google Scholar
Shizukuda Y, Bolan CD, Tripodi DJ, et al. Does oxidative stress modulate left ventricular diastolic function in asymptomatic subjects with hereditary hemochromatosis? Echocardiography. 2009;26:1153–1158.
PubMed Web of Science ®Google Scholar
Oktay AA, Shah SJ. Current perspectives on systemic hypertension in heart failure with preserved ejection fraction. Curr Cardiol Rep. 2014;16:545.
PubMed Web of Science ®Google Scholar
Shah SJ, Aistrup GL, Gupta DK, et al. Ultrastructural and cellular basis for the development of abnormal myocardial mechanics during the transition from hypertension to heart failure. Am J Physiol Heart Circ Physiol. 2014;306:H88–H100.
PubMed Web of Science ®Google Scholar
Rysä J, Leskinen H, Ilves M, et al. Distinct upregulation of extracellular matrix genes in transition from hypertrophy to hypertensive heart failure. Hypertension. 2005;45:927–933.
PubMed Web of Science ®Google Scholar
Mentz RJ, Kelly JP, Von Lueder TG, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2014;64:2281–2293.
PubMed Web of Science ®Google Scholar
DeFuria J, Belkina AC, Jagannathan-Bogdan M, et al. B cells promote inflammation in obesity and type 2 diabetes through regulation of t-cell function and an inflammatory cytokine profile. Proc Natl Acad Sci U S A. 2013;110:5133–5138.
PubMed Web of Science ®Google Scholar
Rovina N, Koutsoukou A, Koulouris NG. Inflammation and immune response in copd: where do we stand? Mediators Inflamm. 2013;2013:413735.
PubMed Web of Science ®Google Scholar
Ter Maaten JM, Damman K, Verhaar MC, et al. Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation. Eur J Heart Fail. 2016;18:588–598.
PubMed Web of Science ®Google Scholar
Pappachan JM, Varughese GI, Sriraman R, et al. Diabetic cardiomyopathy: pathophysiology, diagnostic evaluation and management. World J Diabetes. 2013;4:177–189.
PubMedGoogle Scholar
Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–271.
PubMed Web of Science ®Google Scholar
Van Heerebeek L, Hamdani N, Falcão-Pires I, et al. Low myocardial protein kinase g activity in heart failure with preserved ejection fraction. Circulation. 2012;126:830–839.
PubMed Web of Science ®Google Scholar
Westermann D, Lindner D, Kasner M, et al. Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction. Circ Heart Fail. 2011;4:44–52.
PubMed Web of Science ®Google Scholar
Franssen C, Chen S, Unger A, et al. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail. 2016;4:312–324.
PubMed Web of Science ®Google Scholar
Yturralde FR, Gaasch WH. Diagnostic criteria for diastolic heart failure. Prog Cardiovasc Dis. 2005;47:314–319.
PubMed Web of Science ®Google Scholar
Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the american society of echocardiography and the European association of cardiovascular imaging. Eur Heart J Cardiovasc Imaging. 2016;17:1321–1360.
PubMed Web of Science ®Google Scholar
Eskander M, Kern MJ. Invasive hemodynamics of myocardial disease: systolic and diastolic dysfunction (and hypertrophic obstructive cardiomyopathy). Intervent Cardiol Clin. 2017;6:297–307.
PubMedGoogle Scholar
Huis In’t Veld AE, De Man FS, Van Rossum AC, et al. How to diagnose heart failure with preserved ejection fraction: the value of invasive stress testing. Neth Heart J. 2016;24:244–251.
PubMed Web of Science ®Google Scholar
Zile MR, Baicu CF, Gaasch WH, et al. Diastolic heart failure – abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med. 2004;350:1953–1959.
PubMed Web of Science ®Google Scholar
Sato K, Grant ADM, Negishi K, et al. Reliability of updated left ventricular diastolic function recommendations in predicting elevated left ventricular filling pressure and prognosis. Am Heart J. 2017;189:28–39.
PubMed Web of Science ®Google Scholar
Morris DA, Ma X, Belyavskiy E, et al. Left ventricular longitudinal systolic function analysed by 2d speckle-tracking echocardiography in heart Failure with preserved ejection fraction: a meta-analysis. Open Heart. 2017;4:e000630.
PubMedGoogle Scholar
Park S, Miyazaki C, Bruce CJ, et al. Left ventricular torsion by two-dimensional speckle tracking echocardiography in patents with diastolic dysfunction and normal ejection fraction. J Am Soc Echocardiogr. 2008;21:1129–1137.
PubMed Web of Science ®Google Scholar
Zhou W, Benharash P, Ho J, et al. Left ventricular twist and untwist rate provide reliable measures of ventricular function in myocardial ischemia and a wide range of hemodynamic states. Physiol Rep. 2013;1:e00110.
PubMedGoogle Scholar
Leong DP, De Pasquale CG, Selvanayagam JB, et al. Heart failure with normal ejection fraction: the complementary roles of echocardiography and cmr imaging. JACC Cardiovasc Imaging. 2010;3:409–420.
PubMed Web of Science ®Google Scholar
Dusch MN, Thadani SR, Dhillon GS, et al. Diastolic function assessed by cardiac mri using longitudinal left ventricular fractional shortening. Clin Imaging. 2014;38:666–668.
PubMed Web of Science ®Google Scholar
Wu V, Chyou JY, Chung S, et al. Evaluation of diastolic function by three-dimensional volume tracking of the mitral annulus with cardiovascular magnetic resonance: comparison with tissue doppler imaging. J Cardiovasc Magn Reson. 2014;16:71.
PubMed Web of Science ®Google Scholar
Su MM, Lin L, Tseng YE, et al. CMR-verified diffuse myocardial fibrosis is associated with diastolic dysfunction in HFpEF. JACC Cardiovasc Imaging. 2014;7:991–997.
PubMed Web of Science ®Google Scholar
Kurita A, Kono K, Morita H. Diastolic cardiac function is synonymous with long-axis systolic function: a novel concept in cardiac function. Echocardiography. 2012;29:397–402.
PubMed Web of Science ®Google Scholar
Borlaug BA, Nishimura RA, Sorajja P, et al. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3:588–595.
PubMed Web of Science ®Google Scholar
Obokata M, Kane GC, Reddy YN, et al. The role of diastolic stress testing in the evaluation for HFpEF: A simultaneous invasive-echocardiographic study. Circulation. 2017;135:825–838.
PubMed Web of Science ®Google Scholar
Van Iterson EH, Olson TP, Borlaug BA, et al. Comparisons of noninvasive methods used to assess exercise stroke volume in heart failure with preserved ejection fraction. Med Sci Sports Exerc. 2017;49:1758–1768.
PubMed Web of Science ®Google Scholar
Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. J Card Fail. 2017;23:628–651.
PubMed Web of Science ®Google Scholar
Fu S, Ping P, Wang F, et al. Synthesis, secretion, function, metabolism, and application of natriuretic peptides in heart failure. J Biol Eng. 2018;12:2.
PubMed Web of Science ®Google Scholar
Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of b-type natriuretic peptide in the emergency diagnosis of heart failure. The New England Journal of Medicine. 2002;347:161–167.
PubMed Web of Science ®Google Scholar
Kelder JC, Cramer MJ, Van Wijngaarden J, et al. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation. 2011;124:2865–2873.
PubMed Web of Science ®Google Scholar
Van Veldhuisen DJ, Linssen GCM, Jaarsma T, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013;61:1498–1506.
PubMed Web of Science ®Google Scholar
Uraizee I, Cheng S, Hung C, et al. Relation of N-terminal pro-b-type natriuretic peptide with diastolic function in hypertensive heart disease. Am J Hypertens. 2013;26:1234–1241.
PubMed Web of Science ®Google Scholar
Meluzin J, Tomandl J. Can biomarkers help to diagnose early heart failure with preserved ejection fraction. Dis Markers. 2015;2015:426045.
PubMedGoogle Scholar
Parikh RH, Seliger SL, Christenson R, et al. Soluble ST2 for prediction of heart failure and cardiovascular death in an elderly, community-dwelling population. J Am Heart Assoc. 2016;5:e003188.
PubMed Web of Science ®Google Scholar
Santhanakrishnan R, Chong JP, Ng TP, et al. Growth differentiation factor 15, st2, high-sensitivity troponin t, and n-terminal pro Brain natriuretic peptide in heart failure with preserved vs reduced ejection fraction. Eur J Heart Fail. 2012;14:1338–1347.
PubMed Web of Science ®Google Scholar
De Boer RA, Edelmann F, Cohen-Solal A, et al. Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail. 2013;15:1095–1101.
PubMed Web of Science ®Google Scholar
Carrasco-Sanchez FJ, Aramburu-Bodas O, Salamanca-Bautista P. Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction. Int J Cardiol. 2013;169:177–182.
PubMed Web of Science ®Google Scholar
Lopez B, Gonzalez A, Querejeta R, et al. Association of Cardiotrophin-1 With Myocardial Fibrosis in Hypertensive Patients With Heart Failure. Hypertension. 2014;63:483–489.
PubMed Web of Science ®Google Scholar
Celik A, Sahin S, Koc F, et al. Cardiotrophin-1 plasma levels are increased in patients with diastolic heart failure. Med Sci Monit. 2012;18:CR25–31.
PubMed Web of Science ®Google Scholar
Chan MMY, Santhanakrishnan R, Chong JPC, et al. Growth differentiation factor 15 in heart failure with preserved vs reduced ejection fraction. Eur J Heart Fail. 2016;18:81–88.
PubMed Web of Science ®Google Scholar
Tromp J, Van Der Pol A, Klip IT, et al. Fibrosis marker syndecan-1 and outcome in patients with heart failure with reduced and preserved ejection fraction. Circ Heart Fail. 2014;7:457–462.
PubMed Web of Science ®Google Scholar
Sinning C, Kempf T, Schwarzl M, et al. Biomarkers for characterization of heart failure – distinction of heart failure with preserved and reduced ejection fraction. Int J Cardiol. 2017;15:272–277.
Google Scholar
Edelmann F, Holzendorf V, Wachter R, et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur J Heart Fail. 2015;17:214–223.
PubMed Web of Science ®Google Scholar
Tromp J, Khan MA, Klip IT, et al. Biomarker profiles in heart failure patients with preserved and reduced ejection fraction. J Am Heart Assoc. 2017;6:e003989.
PubMed Web of Science ®Google Scholar
Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on Mortality and Cardiovascular Hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215–225.
PubMed Web of Science ®Google Scholar
Conraads VM, Metra M, Kamp O, et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail. 2012;14:219–225.
PubMed Web of Science ®Google Scholar
Hernandez AF, Hammill BG, O’Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol. 2009;53:184–192.
PubMed Web of Science ®Google Scholar
Yamamoto K, Origasa H, Hori M, et al. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail. 2013;15:110–118.
PubMed Web of Science ®Google Scholar
Kosmala W, Rojek A, Przewlocka-Kosmala M, et al. Effect of aldosterone antagonism on exercise tolerance in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2016;68:1823–1834.
PubMed Web of Science ®Google Scholar
Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383–1392.
PubMed Web of Science ®Google Scholar
Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309:781–791.
PubMed Web of Science ®Google Scholar
Upadhya B, Hundley WG, Brubaker PH, et al. Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction. J Am Geriatr Soc. 2017;65:2374–2382.
PubMed Web of Science ®Google Scholar
Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456–2467.
PubMed Web of Science ®Google Scholar
Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet. 2003;362:777–781.
PubMed Web of Science ®Google Scholar
Cleland JG, Tendera M, Adamus J, et al. The Perindopril in Elderly People With Chronic Heart Failure (PEP-CHF) study. Eur Heart J. 2006;27:2338–2345.
PubMed Web of Science ®Google Scholar
Komajda M, Isnard R, Cohen-Solal A, et al. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail. 2017;19:1495–1503.
PubMed Web of Science ®Google Scholar
Kosmala W, Holland DJ, Rojek A, et al. Effect of if-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol. 2013;62:1330–1338.
PubMed Web of Science ®Google Scholar
Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268–1277.
PubMed Web of Science ®Google Scholar
Liu LC, Hummel YM, Van Der Meer P, et al. Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. Eur J Heart Fail. 2017;19:116–125.
PubMed Web of Science ®Google Scholar
Redfield MM, Anstrom KJ, Levine JA, et al. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med. 2015;373:2314–2324.
PubMed Web of Science ®Google Scholar
Filippatos G, Maggioni AP, Lam CSP, et al. Patient-reported outcomes in the sluble guanylate cyclase stimulator in heart failure patient with preserved ejection fraction (SOCRATES-PRESERVED) study. Eur J Heart Fail. 2017;19:782–791.
PubMed Web of Science ®Google Scholar
Solomon SD, Zile M, Pieske B, et al. Prospective comparison of arni with arb on management of heart failure with preserved ejection fraction (PARAMOUNT) investigators. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387–1395.
PubMed Web of Science ®Google Scholar
Tsujimoto T, Kajio H. Favorable effects of statins in the treatment of heart failure with preserved ejection fraction in patients without ischemic heart disease. Int J Cardiol. 2018;255:111–117.
PubMed Web of Science ®Google Scholar
Fukuta H, Goto T, Wakami K, et al. The effect of statins on mortality in heart failure with preserved ejection fraction: a meta-analysis of propensity score analyses. Int J Cardiol. 2016;214:301–306.
PubMed Web of Science ®Google Scholar
Alehagen U, Benson L, Edner M, et al. Association between use of statins and mortality in patients with heart failure and ejection fraction of ≥50. Circ Heart Fail. 2015;8:862–870.
PubMed Web of Science ®Google Scholar
Van Tassell BW, Arena R, Biondi-Zoccai G, et al. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart Failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol. 2014;113:321–327.
PubMed Web of Science ®Google Scholar
Edelmann F, Gelbrich G, Düngen HD, et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise Training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol. 2011;58:1780–1791.
PubMed Web of Science ®Google Scholar
Smart N, Haluska B, Jeffriess L, et al. Exercise training in systolic and diastolic dysfunction: effects on cardiac function, functional capacity, and quality of life. Am Heart J. 2007;153:530–536.
PubMed Web of Science ®Google Scholar
Adamopoulos S, Parissis J, Kroupis C, et al. Physical training reduces peripheral markers of inflammation in patients with chronic heart failure. Eur Heart J. 2001;22:791–797.
PubMed Web of Science ®Google Scholar
Pandey A, Parashar A, Kumbhani D, et al. Exercise training in patients with heart failure and preserved ejection fraction: meta-analysis of randomized control trials. Circ Heart Fail. 2015;8:33–40.
PubMed Web of Science ®Google Scholar
Feldman T, Mauri L, Kahwash R, et al. Transcatheter interatrial shunt device for the treatment of heart failure with preserved ejection fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A phase 2, randomized, sham-controlled trial. Circ. 2018;137:364–375.
PubMed Web of Science ®Google Scholar
Hasenfuß G, Hayward C, Burkhoff D, et al. A transcatheter intracardiac shunt device for heart failure with preserved ejection fraction (REDUCE LAP-HF): a multicentre, open-label, single-arm, phase 1 trial. Lancet. 2016;387:1298–1304.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Mechanisms, diagnosis, and treatment of heart failure with preserved ejection fraction and diastolic dysfunction

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date